CRISPR Therapeutics Profitability Analysis

CRSP
 Stock
  

USD 78.90  1.44  1.86%   

For CRISPR Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of CRISPR Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well CRISPR Therapeutics AG utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between CRISPR Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of CRISPR Therapeutics AG over time as well as its relative position and ranking within its peers. Continue to Trending Equities.
  
As of 12th of August 2022, Price to Sales Ratio is likely to grow to 6.46. Also, Return on Sales is likely to grow to 0.45. CRISPR Therapeutics Consolidated Income is very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Consolidated Income of 377.66 Million. As of 12th of August 2022, Net Income is likely to grow to about 407.5 M, while Preferred Dividends Income Statement Impact is likely to drop about 666.6 K.

CRISPR Therapeutics Revenues

987.2 Million

Is CRISPR Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CRISPR Therapeutics. If investors know CRISPR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CRISPR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
B
Quarterly Revenue Growth YOY
-1.0
Return On Assets
-0.15
Return On Equity
-0.27
The market value of CRISPR Therapeutics is measured differently than its book value, which is the value of CRISPR that is recorded on the company's balance sheet. Investors also form their own opinion of CRISPR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CRISPR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CRISPR Therapeutics' market value can be influenced by many factors that don't directly affect CRISPR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CRISPR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine CRISPR Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CRISPR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

CRISPR Therapeutics Number of Shares Shorted vs. Current Ratio Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining CRISPR Therapeutics's current stock value. Our valuation model uses many indicators to compare CRISPR Therapeutics value to that of its competitors to determine the firm's financial worth.
CRISPR Therapeutics AG is number one stock in current ratio category among related companies. It is number one stock in number of shares shorted category among related companies making about  579,980  of Number of Shares Shorted per Current Ratio. CRISPR Therapeutics Current Ratio is very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Current Ratio of 20.17. Comparative valuation analysis is a catch-all model that can be used if you cannot value CRISPR Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for CRISPR Therapeutics' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the CRISPR Therapeutics' earnings, one of the primary drivers of an investment's value.

CRISPR Number of Shares Shorted vs. Current Ratio

Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
CRISPR Therapeutics 
Current Ratio 
 = 
Current Asset 
Current Liabilities 
19.88 X
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
CRISPR Therapeutics 
Shares Shorted 
 = 
Shorted by Public 
by Institutions 
11.53 M
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.

CRISPR Number of Shares Shorted Comparison

CRISPR Therapeutics is currently under evaluation in number of shares shorted category among related companies.

CRISPR Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in CRISPR Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, CRISPR Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of CRISPR Therapeutics' change in net profit over the period of time. It can combine multiple indicators of CRISPR Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for 2022
Accumulated Other Comprehensive Income-5.1 M-5.2 M
Consolidated Income377.7 M407.5 M
Net Income377.7 M407.5 M
Net Income Common Stock377.7 M407.5 M
Net Income to Non Controlling Interests-28.8 K-31 K
Operating Income373.5 M403 M
Preferred Dividends Income Statement Impact670.5 K666.6 K
Income Tax Expense1.9 MM
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats CRISPR-associated protein 9 platform. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. CRISPR Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 473 people.

CRISPR Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on CRISPR Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of CRISPR Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the CRISPR Therapeutics' important profitability drivers and their relationship over time.

CRISPR Therapeutics Profitability Trends

CRISPR Therapeutics profitability trend refers to the progression of profit or loss within a business. An upward trend means that CRISPR Therapeutics' profit has generally increased over time, and a downward profitability trend means profits are declining. Recognizing problems early in profitability trends allows investors to address revenue and cost issues in advance. Investors and analysts usually monitor three types of profitability trends: gross, operating, and net. Gross profit is the difference between revenue and costs of goods sold. Operating profit is CRISPR Therapeutics' gross profit minus its overhead. After you account for other unusual revenue, expenses, and costs, you get net profit. Gross profit trends are often a good indicator of future profitability. If you have high gross profit margins, you have a better chance to cover overhead and make money.

CRISPR Therapeutics Profitability Drivers Correlations

One of the toughest challenges investors face today is learning how to quickly synthesize and read into endless financial statements and information provided by the company, SEC reporting, and various external parties. Understanding the correlation between CRISPR Therapeutics different financial indicators related to revenue and profit generation helps investors identify and prioritize their investing strategies towards CRISPR Therapeutics in a much-optimized way. Analyzing correlations between profit drivers that are directly associated with dollar figures is the most effective way to break down CRISPR Therapeutics' future profitability.

Use CRISPR Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CRISPR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CRISPR Therapeutics will appreciate offsetting losses from the drop in the long position's value.

CRISPR Therapeutics Pair Trading

CRISPR Therapeutics AG Pair Trading Analysis

The ability to find closely correlated positions to CRISPR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CRISPR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CRISPR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CRISPR Therapeutics AG to buy it.
The correlation of CRISPR Therapeutics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CRISPR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CRISPR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CRISPR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your CRISPR Therapeutics position

In addition to having CRISPR Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Investing Thematic Idea Now

Investing
Investing Theme
Companies involved in money management and investment banking services. The Investing theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Investing Theme or any other thematic opportunities.
View All  Next Launch
Continue to Trending Equities. Note that the CRISPR Therapeutics information on this page should be used as a complementary analysis to other CRISPR Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Complementary Tools for CRISPR Stock analysis

When running CRISPR Therapeutics price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
To fully project CRISPR Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of CRISPR Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include CRISPR Therapeutics' income statement, its balance sheet, and the statement of cash flows.
Potential CRISPR Therapeutics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although CRISPR Therapeutics investors may work on each financial statement separately, they are all related. The changes in CRISPR Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on CRISPR Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.